A promising new COVID-19 vaccine candidate developed by researchers at the Centenary Institute and the University of Sydney ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

A research team with Professor Neha Kamat used synthetic liposomes and bacterial extracts to generate immune responses ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...

AI also supports reverse vaccinology, where pathogen genomes are computationally analyzed to identify immunogenic regions ...

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...

Partial immunity from COVID in residents early in the pandemic and infection-prevention measures may explain the findings, ...

SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...

Dr. Joseph Ladapo called on federal agencies to expand research into what he calls vaccine “injuries,” alongside research ...

Learn how olive oil's anti-inflammatory components helped create a less painful and longer lasting mRNA vaccine, and showed ...

Researchers from the Centenary Institute and the University of Sydney created the CoVEXS5 vaccine, which protects against ...